Reports Q1 revenue $253.5M, consensus $241.96M. "We are pleased to report another strong quarter of performance serving the Duchenne community. With EXONDYS 51, VYONDYS 53, and AMONDYS 45, we once again exceeded analyst estimates, with total revenue for the quarter reaching $253.5 million and net product revenue standing at $231.5 million and growing at 23% versus the same quarter of prior year. The Sarepta team has consistently performed and served the patient community over the last 6 years and it will be this team, with its track record of success, that will launch and serve the community in the United States with SRP-9001 if our BLA is approved," said Doug Ingram, president and chief executive officer, Sarepta. "We look forward to sharing the totality of evidence supporting the safety and efficacy of SRP-9001 at the upcoming advisory committee meeting on May 12 and at the same time continuing to prepare for the launch of SRP-9001 in the United States."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SRPT:
- SRPT Upcoming Earnings Report: What to Expect?
- Sarepta initiated with an Outperform at SMBC Nikko
- William Blair biotech analyst to hold an analyst/industry conference call
- Catalent concerns ‘may be overstated’ for Sarepta, says RBC Capital
- Sarepta sees no impact on SRP-9001 from Catalent update, says BofA
